Abstract

Research Article

Severe Alcoholic Hepatitis-optimizing Medical Management: Whether we need a Liver Transplant

Harshal Rajekar*

Published: 09 July, 2024 | Volume 8 - Issue 1 | Pages: 006-016

Severe alcoholic hepatitis is an ethical and clinical conundrum, wherein a liver transplant is often recommended. The adequacy of medical treatment versus the risk of recidivism after transplant is often debated. Complete recovery in 26 of 27 patients with severe alcoholic hepatitis was observed, and hence the data was retrospectively analysed.
Methods: 27 patients, with severe alcoholic hepatitis, with Maddrey's discriminant function between 59.7 to 165.2 (mean 107.53), from June 2017 to May 2022, were followed up for between 11 months to 6 years. INR ranged from 1.99 to 3.7 (mean 2.709), and bilirubin was between 7.6 to 37.01, (mean 20.859). 8 patients had pre-existing liver cirrhosis. All patients received probiotics, nutritional support, physical rehabilitation, saturated fat (clarified butter/ desi ghee) supplementation, and anti-oxidant support. 
At 90 days, total bilirubin improved to between 1.0 to 6.8 (mean 2.625). ALT (Alanine Transaminase/ SGPT) ranged from 65 to 550 (mean ALT – 197); and AST (Aspartate Transaminase / SGOT) ranged from 58 to 810 (mean AST – 271.51). Both the AST and ALT were near normal after 90 days. One patient died due to bacterial pneumonia and sepsis; the remaining 26 patients made a complete recovery. All patients including those with diagnosed liver cirrhosis, had complete resolution of their ascites, and near-normal liver function. At the last outpatient visit, none had ascites, edema, or encephalopathy, and had normal albumin levels and INR values. 
Conclusion: Probiotics, nutrition, a saturated fat diet, and exercise; all have shown benefits in patients with severe alcoholic hepatitis when tested individually. Concomitant use of all the above has not been reported in the treatment of alcoholic hepatitis. The role of nutrition alone versus the contribution of nutritional deficiencies and the role of gut-derived endotoxemia need to be studied in detail. How to identify patients who need a transplant, if it is needed at all, remains a challenge.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001045 Cite this Article Read Full Article PDF

Keywords:

Severe alcoholic hepatitis; Liver transplant; Probiotics; Nutrition; Reversible liver failure; Saturated fat diet

References

  1. https://www.statista.com/statistics/727026/consumption-of-alcoholic-beverages-india/#:~:text=Alcohol%20consumption%20in%20India%20amounted,growing%20urban%20population%20among%20others.
  2. Gupta M, Kulamarwa G, Ranjan P, Bhargawa N, Dadhich S. Alcohol drinking pattern and alcohol-related liver disease in India. Indian J Gastroenterol. 2005;24:Suppl 2.
  3. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193-199. Available from: https://pubmed.ncbi.nlm.nih.gov/352788/
  4. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655. Available from: https://pubmed.ncbi.nlm.nih.gov/7165009/
  5. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758-2769. Available from: https://pubmed.ncbi.nlm.nih.gov/19553649/
  6. Asrani SK, Kamath PS, Pedersen R, Jennifer S, Barbara Y, Terry MT, et al. Liver-related mortality in the US is underestimated. Hepatology. 2010;52(2):408-410. Available from: https://journals.lww.com/hep/citation/2010/10001/liver_related_mortality_in_the_us_is.175.aspx
  7. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25(1):108-111. Available from: https://pubmed.ncbi.nlm.nih.gov/8985274/
  8. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193-199. Available from: https://pubmed.ncbi.nlm.nih.gov/352788/
  9. Farfan Labonne BE, Gutierrez M, Gomez-Quiroz LE, et al. Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage. Cell Biol Toxicol. 2009;25:599-609. Available from: https://pubmed.ncbi.nlm.nih.gov/19137438/
  10. Ramaiah SK, Jaeschke H. Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury. Toxicol Mech Methods. 2007;17:431-440. Available from: https://pubmed.ncbi.nlm.nih.gov/20020946/
  11. Kendrick SF, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones DE, et al. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology. 2010;51:1988-1997. Available from: https://pubmed.ncbi.nlm.nih.gov/20232292/
  12. Saso K, Moehren G, Higashi K, Hoek JB. Differential inhibition of epidermal growth factor signaling pathways in rat hepatocytes by long-term ethanol treatment. Gastroenterology. 1997;112(6):2073-88. Available from: https://pubmed.ncbi.nlm.nih.gov/9178701/
  13. Baptista A, Bianchi L, de Groote J. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet. 1981;1:707-711. Available from: https://pubmed.ncbi.nlm.nih.gov/6110925/
  14. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1):307-28. Available from: https://pubmed.ncbi.nlm.nih.gov/20034030/
  15. Dhanda AD, Collins PL, McCune CA. Is liver biopsy necessary in the management of alcoholic hepatitis? World J Gastroenterol. 2013;19(44):7825-7829. Available from: https://pubmed.ncbi.nlm.nih.gov/24307775/
  16. Hamid R, Forrest EH. Is histology required for the diagnosis of alcoholic hepatitis? A review of published randomised controlled trials. Gut. 2011;60 Suppl 1. Available from: https://gut.bmj.com/content/60/Suppl_1/A233.1
  17. Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2014;146(5):1231-9.e1-6. Available from: https://pubmed.ncbi.nlm.nih.gov/24440674/
  18. Im GY, Lucey MR. Practical Concerns and Controversies in the Management of Alcoholic Hepatitis. Gastroenterol Hepatol (N Y). 2016;12(8):478-489. Available from: https://pubmed.ncbi.nlm.nih.gov/27917083/
  19. Gomes GF, Pisani JC, Macedo ED, Campos AC. The nasogastric feeding tube as a risk factor for aspiration and aspiration pneumonia. Curr Opin Clin Nutr Metab Care. 2003;6(3):327-333. Available from: https://pubmed.ncbi.nlm.nih.gov/12690267/
  20. Cabre E, Gonzalez-Huix F, Abad-Lacruz A, Esteve M, Acero D, Fernandez-Bañares F, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology. 1990;98(3):715-720. Available from: https://pubmed.ncbi.nlm.nih.gov/2105256/
  21. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154-181. Available from: https://pubmed.ncbi.nlm.nih.gov/29628280/
  22. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance - From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333. Available from: https://pubmed.ncbi.nlm.nih.gov/31314133/
  23. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int. 2015;35(12):2072-2078. Available from: https://pubmed.ncbi.nlm.nih.gov/25645300/
  24. Daures JP, Peray P, Bories P, Blanc P, Yousfi A, Michel H, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis. Gastroenterol Clin Biol. 1991;15(3):223-228. Available from: https://pubmed.ncbi.nlm.nih.gov/1828447/
  25. Reynolds TB, Benhamou JP, Blake J, Naccarato R, Orrego H. Treatment of alcoholic hepatitis. Gastroenterol Int. 1989;2:208–216.
  26. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990;113(5):299-307. Available from: https://pubmed.ncbi.nlm.nih.gov/2142869/
  27. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut. 1995;37(1):113-118. Available from: https://pubmed.ncbi.nlm.nih.gov/7672658/
  28. Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36(4):480-487. Available from: https://pubmed.ncbi.nlm.nih.gov/11943418/
  29. Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155(2):458-468. Available from: https://pubmed.ncbi.nlm.nih.gov/29738698/
  30. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(6):1637-1648. Available from: https://pubmed.ncbi.nlm.nih.gov/11113085/
  31. McHutchison JG, Runyon BA, Draguesku JO. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology. 1991;14(4 Pt 2):96A.
  32. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev. 2009;(4):CD007339. Available from: https://pubmed.ncbi.nlm.nih.gov/19821406/
  33. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15(13):1613-161 Available from: https://pubmed.ncbi.nlm.nih.gov/19340904/
  34. Park SH, Kim DJ, Kim YS, Yim HJ, Tak WY, Lee HJ, et al. Korean Association for the Study of the Liver (KASL)-Alcohol Related Problems Study Group. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol. 2014;61(4):792-79 Available from: https://pubmed.ncbi.nlm.nih.gov/24845609/
  35. Sidhu SS, Goyal O, Singla M, Bhatia KL, Chhina RS, Sood A. Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. J Assoc Physicians India. 2012;60:20-22. Available from: https://pubmed.ncbi.nlm.nih.gov/23029716/
  36. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619-1628. Available from: https://pubmed.ncbi.nlm.nih.gov/25901427/
  37. Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1781-1789. Available from: https://pubmed.ncbi.nlm.nih.gov/22070475/
  38. Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53(6):1117-11 Available from: https://pubmed.ncbi.nlm.nih.gov/20801542/
  39. Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol. 2007;47(2):277-2 Available from: https://pubmed.ncbi.nlm.nih.gov/17532088/
  40. Floersheim GL. Treatment of human amatoxin mushroom poisoning. Myths and advances in therapy. Med Toxicol. 1987;2(1):1-9. Available from: https://pubmed.ncbi.nlm.nih.gov/3547003/
  41. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9(1):105-1 Available from: https://pubmed.ncbi.nlm.nih.gov/2671116/
  42. Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28(4):615-6 Available from: https://pubmed.ncbi.nlm.nih.gov/9566830/
  43. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005;100(11):2583-25 Available from: https://pubmed.ncbi.nlm.nih.gov/9566830/
  44. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2002;2002(2): CD002800. Available from: https://pubmed.ncbi.nlm.nih.gov/12076451/
  45. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev. 2005;2005(2):CD002148. Available from: https://pubmed.ncbi.nlm.nih.gov/15846629/
  46. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev. 2006;(2): CD002235. Available from: https://pubmed.ncbi.nlm.nih.gov/16625556/
  47. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27:1765–1772. Available from: https://pubmed.ncbi.nlm.nih.gov/14634492/
  48. Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109(9):1417-1423. Available from: https://pubmed.ncbi.nlm.nih.gov/24935272/
  49. Nahas J, Tow CY, Chacko KR, Haider T, Massoumi H. Granulocyte colony-stimulating factor does not improve mortality in severe alcoholic hepatitis: a single-center experience from the United States. Gastroenterol Hepatol Bed Bench. 2023;16(1):524-526. Available from: https://pubmed.ncbi.nlm.nih.gov/37070107/
  50. Marot A, Singal AK, Moreno C, Deltenre P. Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020;2(5):100139. Available from: https://pubmed.ncbi.nlm.nih.gov/32775975/
  51. Virovic-Jukic L, Ljubas D, Stojsavljevic-Shapeski S, Ljubičić N, Filipec Kanizaj T, Mikolasevic I, et al. Liver regeneration as treatment target for severe alcoholic hepatitis. World J Gastroenterol. 2022;28(32):4557-4573. Available from: https://pubmed.ncbi.nlm.nih.gov/36157937/
  52. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. CANTOS Pilot Investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739-2748. Available from: https://pubmed.ncbi.nlm.nih.gov/23129601/
  53. Vergis N, Patel VC, Bogdanowicz K. OS034 - Il-1beta signal inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH). J Hepatol. 2022;77–S35.
  54. Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis. 2013. Available from: https://clinicaltrials.gov/show/NCT01809132.  
  55. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390-1397. Available from: https://pubmed.ncbi.nlm.nih.gov/15122768/
  56. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135(6):1953-1960. Available from: https://pubmed.ncbi.nlm.nih.gov/18848937/
  57. Selonsertib in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH). Available from: https://clinicaltrials.gov/show/NCT02854631.  
  58. Study of IDN-6556 in patients with severe alcoholic hepatitis and contraindications to steroid therapy. Available from: https://clinicaltrials.gov/show/NCT01912404.  
  59. Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol. 2018;37(3):215-225. Available from: https://pubmed.ncbi.nlm.nih.gov/29931479/
  60. Philips CA, Ahamed R, Rajesh S, Singh S, Tharakan A, Abduljaleel JK, et al. Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala. Gastroenterol Rep (Oxf). 2022;10:goac074. Available from: https://pubmed.ncbi.nlm.nih.gov/36479155/
  61. Philips CA, Ahamed R, Rajesh S, Abduljaleel JKP, Augustine P. Long-term Outcomes of Stool Transplant in Alcohol-associated Hepatitis-Analysis of Clinical Outcomes, Relapse, Gut Microbiota and Comparisons with Standard Care. J Clin Exp Hepatol. 2022;12(4):1124-1132. Available from: https://pubmed.ncbi.nlm.nih.gov/35814513/
  62. Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S, et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int. 2022;16(2):433-446. Available from: https://pubmed.ncbi.nlm.nih.gov/35349076/
  63. Zhang D, Liu Z, Bai F. Roles of Gut Microbiota in Alcoholic Liver Disease. Int J Gen Med. 2023;16:3735-3746. Available from: https://pubmed.ncbi.nlm.nih.gov/37641627/
  64. Han SH, Suk KT, Kim DJ, Kim MY, Baik SK, Kim YD, et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol. 2015;27:1300-1306. Available from: https://pubmed.ncbi.nlm.nih.gov/26302024/
  65. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575:505-511. Available from: https://pubmed.ncbi.nlm.nih.gov/31723265/
  66. Scheunert CA. About bone softness in horses and dysbiosis of the intestinal flora. Z infection. 1920;21:105-121.
  67. Bode JC, Bode C, Heidelbach R, Dürr HK, Martini GA. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology. 1984;31:30-34. Available from: https://pubmed.ncbi.nlm.nih.gov/6698486/
  68. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, et al. Lactobacillus Gg treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol. 2009;43:163-172. Available from: https://pubmed.ncbi.nlm.nih.gov/19251117/
  69. Huang H, Lin Z, Zeng Y, Lin X, Zhang Y. Probiotic and glutamine treatments attenuate alcoholic liver disease in a rat model. Exp Ther Med. 2019;18:4733-4739. Available from: https://pubmed.ncbi.nlm.nih.gov/31777560/
  70. Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, et al. Recovery of ethanol-induced akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut. 2018;67:891-901. Available from: https://pubmed.ncbi.nlm.nih.gov/28550049/
  71. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42:675-682. Available from: https://pubmed.ncbi.nlm.nih.gov/19038698/
  72. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012;10:815-81 Available from: https://pubmed.ncbi.nlm.nih.gov/22391344/
  73. Douillard FP, de Vos WM. Biotechnology of health-promoting bacteria. Biotechnol Adv. 2019;37:107369. Available from: https://pubmed.ncbi.nlm.nih.gov/30876799/
  74. Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut. 2019;68:1504-1515. Available from: https://pubmed.ncbi.nlm.nih.gov/30448775/
  75. Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, et al. Intestinal virome in patients with alcoholic hepatitis. Hepatology. 2020;72:2182-2196. Available from: https://pubmed.ncbi.nlm.nih.gov/32654263/
  76. Gupta H, Kim SH, Kim SK, Han SH, Kwon HC, Suk KT. Beneficial Shifts in Gut Microbiota by Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 in Alcoholic Hepatitis. Microorganisms. 2022;10(7):1474. Available from: https://pubmed.ncbi.nlm.nih.gov/35889193/
  77. Neuman MG, Seitz HK, French SW, Malnick S, Tsukamoto H, Cohen LB, et al. Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. Biomedicines. 2020;8(3):63. Available from: https://pubmed.ncbi.nlm.nih.gov/32197424/
  78. Fuenzalida C, Dufeu MS, Poniachik J, Roblero JP, Valenzuela-Pérez L, Beltrán CJ. Probiotics-Based Treatment as an Integral Approach for Alcohol Use Disorder in Alcoholic Liver Disease. Front Pharmacol. 2021;12:729950. Available from: https://pubmed.ncbi.nlm.nih.gov/34630107/
  79. Hassanein T, McClain CJ, Vatsalya V, Stein LL, Flamm SL, Martin P, et al. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis. Am J Gastroenterol. 2024;119(1):107-115. Available from: https://pubmed.ncbi.nlm.nih.gov/37011138/
  80. Dominguez M, Miquel R, Colmenero J, Moreno M, García-Pagán JC, Bosch J, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology. 2009;136(5):1639-1650. Available from: https://pubmed.ncbi.nlm.nih.gov/19208360/
  81. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010;52(4):1291-300. Available from: https://pubmed.ncbi.nlm.nih.gov/20842630/
  82. Charbel Issa P, Chong NV, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration — current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol. 2011;249:163-174. Available from: https://pubmed.ncbi.nlm.nih.gov/21127893/
  83. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005;10:3093-3099. Available from: https://pubmed.ncbi.nlm.nih.gov/15970563/
  84. Seth D, Gorrell MD, Cordoba S, McCaughan GW, Haber PS. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol. 2006 Aug;45(2):306-320. Available from: https://pubmed.ncbi.nlm.nih.gov/16797773/
  85. Sidhu SS, Dusseja A, Shalimar, Nijhawan S, Kapoor D, Goyal O, Kishore H. A multicenter double-blind, placebo-controlled randomized trial to evaluate the safety and efficacy of bovine colostrum in the treatment of severe alcoholic hepatitis (SAH). Trials. 2023;24(1):515. Available from: https://pubmed.ncbi.nlm.nih.gov/37568158/
  86. Sidhu S, Goyal O, Gupta A, Kishore H, Gupta A. Corticosteroids and bovine colostrum in treatment of alcoholic hepatitis ‘in extremis’: a pilot study. J Clin Exp Hepatology. 2015;S19-S20. Available from: https://www.jcehepatology.com/article/S0973-6883(15)00150-4/abstract
  87. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299(2):638-644. Available from: https://pubmed.ncbi.nlm.nih.gov/11602676/
  88. Kirpich IA, Petrosino J, Ajami N, Feng W, Wang Y, Liu Y, et al. Saturated and Unsaturated Dietary Fats Differentially Modulate Ethanol-Induced Changes in Gut Microbiome and Metabolome in a Mouse Model of Alcoholic Liver Disease. Am J Pathol. 2016 Apr;186(4):765-7 Available from: https://pubmed.ncbi.nlm.nih.gov/27012191/
  89. ILBS-SAH-01. Available from: https://clinicaltrials.gov/study/NCT04084522?tab=history&a=5
  90. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790-800. Available from: https://pubmed.ncbi.nlm.nih.gov/22070476/
  91. Louvet A, Labreuche J, Moreno C, Vanlemmens C, Moirand R, Féray C, et al; QuickTrans trial study group. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. Lancet Gastroenterol Hepatol. 2022;7(5):416-425. Available from: https://pubmed.ncbi.nlm.nih.gov/35202597/
  92. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-194. Available from: https://pubmed.ncbi.nlm.nih.gov/29336434/
  93. Lucey MR, Im GY, Mellinger JL, Szabo G, Crabb DW. Introducing the 2019 American association for the study of liver diseases guidance on alcohol-associated liver disease. Liver Transpl. 2020;26:14-16. Available from: https://journals.lww.com/lt/citation/2020/01000/introducing_the_2019_american_association_for_the.7.aspx
  94. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353‐ Available from: https://pubmed.ncbi.nlm.nih.gov/15660383/
  95. Singh V, Keisham A, Bhalla A, Sharma N, Agarwal R, Sharma R, et al. Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2018;16(10):1650-1656.e2. Available from: https://pubmed.ncbi.nlm.nih.gov/29391265/

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?